Merck & (MRK) Stock
Large pharmaceutical company with cancer drugs and vaccines. Here's the price, business snapshot, and what's worth knowing about Merck & in June 2026.
Merck & Co. Inc. (MRK) is a large, research-driven pharmaceutical company known for oncology immunotherapy, vaccines, and a diverse prescription drug portfolio. Key products have included blockbuster oncology medicines and widely used vaccines, and the company invests heavily in R&D to advance new treatments across oncology, infectious disease and cardiometabolic areas. With a market capitalisation of about $219 billion, Merck combines steady cash generation with active pipeline development and global commercial reach. Investors should weigh a history of dividend payments and scale against sector-specific risks: clinical trial setbacks, regulatory decisions, patent expiries and pricing pressures. Competitive dynamics and occasional litigation can also affect performance. This summary is general, educational information — not financial advice — and aims to highlight business strengths, growth drivers and common risks so investors can better research whether MRK fits their own risk tolerance and portfolio goals.
Why It’s Moving
Merck slips as analysts flag limited room for upside and lingering pressure from softer guidance.
- Analysts have highlighted a downside gap of about 6%, signaling that Merck’s current valuation may already reflect much of the near-term optimism.
- The stock has been trading with weaker technical momentum, which is reinforcing the view that buyers are waiting for a clearer catalyst before stepping in.
- Investor focus remains on Merck’s next earnings and any updates on guidance, since softer outlook commentary has been a key source of pressure on the shares.
Merck slips as analysts flag limited room for upside and lingering pressure from softer guidance.
- Analysts have highlighted a downside gap of about 6%, signaling that Merck’s current valuation may already reflect much of the near-term optimism.
- The stock has been trading with weaker technical momentum, which is reinforcing the view that buyers are waiting for a clearer catalyst before stepping in.
- Investor focus remains on Merck’s next earnings and any updates on guidance, since softer outlook commentary has been a key source of pressure on the shares.
When is the next earnings date for Merck & Co. (MRK)?
Merck’s next earnings date is expected to be August 4, 2026. The report should cover Q2 2026 results. This date is consistent with Merck’s recent late-July to early-August reporting pattern, though the company has not always confirmed the date well in advance.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Merck's stock with a target price of $130.33, indicating potential growth.
Financial Health
Merck & Co. is performing strongly with high revenue, profitability, and cash flow metrics.
Dividend
Merck & Co.'s dividend yield of 2.74% offers a moderate return for investors seeking dividends. If you invested $1000 you would be paid $32.80 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring MRK
US Pharma Reshoring | CDMOs & Supply Chain Stocks
The Trump administration is implementing sweeping 100% tariffs on imported brand-name drugs to force pharmaceutical companies into producing their medicines stateside. This aggressive policy shift creates a highly lucrative environment for US-based contract manufacturers and domestic healthcare supply chain operators as global drugmakers rush to reshore their operations.
Published: 4 April 2026
Explore BasketBiotech Patent Dispute Explained (BioNTech vs Moderna)
BioNTech is suing Moderna for patent infringement over its next-gen COVID-19 vaccine, escalating the legal rivalry between the two biotech leaders. This dispute creates a potential opening for other vaccine developers to gain a competitive edge while the giants are locked in a legal battle.
Published: 20 February 2026
Explore BasketPharma Buyouts Explained | Healthcare M&A Analysis
Merck's decision to end its acquisition talks with Revolution Medicines highlights the high-stakes environment for biotech M&A. This failed deal could signal an opportunity for other pharmaceutical giants to acquire promising oncology assets, creating a ripple effect across the sector.
Published: 26 January 2026
Explore BasketU.S. Drug Manufacturing | Multi-Billion Investment Push
Johnson & Johnson is the latest major drugmaker to lower U.S. prices in exchange for tariff exemptions, joining a broad industry trend. This government-led initiative is sparking a multi-billion dollar investment wave into domestic manufacturing, creating a significant opportunity for companies supporting the U.S. pharmaceutical supply chain.
Published: 10 January 2026
Explore BasketRadiopharma Revolution: Promise Meets Market Risk
Aktis Oncology's highly successful and upsized IPO, strongly backed by pharma giant Eli Lilly, signals a surge of investor confidence in radiopharmaceutical cancer therapies. This theme focuses on the companies poised to ride this wave of investment and innovation in one of biotech's most promising frontiers.
Published: 9 January 2026
Explore BasketDrug Pricing Power | Major Pharma Stocks 2025
Following plans by major drugmakers to raise prices on hundreds of medications, the pharmaceutical industry is showcasing its significant pricing power. This development highlights an investment opportunity centered on established pharmaceutical companies capable of translating market dominance into revenue growth.
Published: 2 January 2026
Explore BasketPharma Reshoring Explained | Manufacturing Investment
Major pharmaceutical firms have signed agreements with the U.S. government to lower drug prices in exchange for tariff exemptions and other concessions. This move is expected to drive over $150 billion in new domestic R&D and manufacturing investments, creating opportunities for U.S.-based life sciences and industrial supply chain companies.
Published: 21 December 2025
Explore BasketCancer Therapies: What's Next After 100% Response Rate
Regeneron's announcement of a 100% response rate for its new lymphoma therapy highlights a major advancement in cancer treatment. This breakthrough creates an investment opportunity centered on companies pioneering next-generation immuno-oncology drugs, particularly those developing bispecific antibodies and other innovative platforms.
Published: 7 December 2025
Explore BasketM&A Activity Overview | Pharma Biotech Investments
Merck's $9.2 billion acquisition of Cidara Therapeutics aims to bolster its antiviral portfolio ahead of the Keytruda patent expiration. This strategic purchase signals a broader investment opportunity in biotech firms with advanced clinical assets, positioning them as attractive targets for major pharmaceutical companies.
Published: 15 November 2025
Explore BasketPharma Onshoring: What's Next for US Drug Supply
Merck is investing $3 billion in a new Virginia plant, signaling a major push for domestic pharmaceutical production. This theme focuses on companies poised to benefit from the broader trend of onshoring the U.S. drug supply chain.
Published: 21 October 2025
Explore BasketGlobal Pharma Titans | Brazil Healthcare Investment
Brazil's large and innovative pharmaceutical market presents a significant area of interest for those looking at global healthcare trends. This basket provides exposure to leading US and EU-listed pharmaceutical and biotech companies with substantial operations, partnerships, or sales within Brazil.
Published: 16 October 2025
Explore BasketPharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: 12 October 2025
Explore BasketDomestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: 26 September 2025
Explore BasketNovo Nordisk Stock Risks: Healthcare Diversification
As Africa's healthcare needs grow, demand for innovative treatments for chronic conditions like diabetes is on the rise. This basket offers potential exposure to this trend through leading global pharmaceutical and healthcare companies listed on US and EU exchanges.
Published: 23 September 2025
Explore BasketJohnson & Johnson (Healthcare Diversification)
As Nigeria's population seeks stable growth opportunities, the global healthcare sector offers a compelling theme for portfolio diversification. This basket provides exposure through a collection of US and EU-listed industry leaders in pharmaceuticals, medical devices, and consumer health.
Published: 16 September 2025
Explore BasketObesity Treatment (Pharma Giants vs Biotech Firms)
Novo Nordisk's major restructuring, driven by intense competition from Eli Lilly, highlights the high-stakes battle in the weight-loss drug market. This theme focuses on other pharmaceutical companies that could benefit from this rivalry, either as innovators with next-generation treatments or as potential acquisition targets.
Published: 10 September 2025
Explore BasketPharma's Pricing Pressure
In response to a presidential ultimatum for 17 drug makers to slash U.S. prices, the pharmaceutical industry faces a major regulatory challenge. This event creates a potential investment opportunity in companies positioned to gain from the pricing disruption, including generic manufacturers.
Published: 3 August 2025
Explore BasketBuffett's Billions: The Philanthropy Effect
Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.
Published: 1 July 2025
Explore BasketOnly Game In Town
These companies have achieved such dominance that they face little to no real competition in their markets. Our analysts have carefully selected businesses with unmatched market power, creating stability and sustained profitability that comes from being the only real choice in their sectors.
Published: 20 June 2025
Explore BasketSleep Well At Night Portfolio
A collection of premium defensive stocks expertly selected by our analysts to help protect your investments during market turbulence. These industry giants offer stability through consistent earnings, reliable dividends, and proven resilience in any economic climate.
Published: 18 June 2025
Explore BasketMarket Indecision
Find refuge from market volatility with these carefully selected companies providing essential goods and services. Our professional analysts have handpicked high-quality, dividend-paying stocks in defensive sectors that offer stability when economic futures look uncertain.
Published: 18 June 2025
Explore BasketCompanies That Give Back
Channel your investments toward companies that make philanthropy a priority. These stocks have been carefully selected by our analysts for their commitment to giving back while building sustainable businesses that could deliver long-term value to investors.
Published: 17 June 2025
Explore BasketBest In Class
Meet the true champions of the market. These carefully selected stocks represent the single most influential company in each economic sector, chosen by expert analysts for their market dominance and enduring competitive advantages.
Published: 17 June 2025
Explore BasketProfit Sharers
These established market leaders don't just generate impressive profits—they're committed to sharing that wealth with you. Carefully selected by our analysts, these dividend powerhouses offer both reliable income streams and the stability of industry-leading businesses.
Published: 17 June 2025
Explore BasketMercury Retrograde
A collection of stable, essential businesses selected by financial experts to help protect your investments during market turbulence. These companies provide the goods and services people need every day, regardless of economic conditions.
Published: 17 June 2025
Explore BasketBoomer Stocks
Discover a collection of iconic, industry-leading companies with deep market roots and reliable dividend histories. These household names have been carefully selected by our analysts for their strong brands, steady cash flow, and potential for long-term stability.
Published: 17 June 2025
Explore BasketLow Volatility Stocks
Are you feeling seasick? Sail through calmer waters with these lower volatility investments. These handpicked stocks were carefully selected by our analysts for their history of stability and potential for consistent returns over time.
Published: 21 May 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: 6 May 2025
Explore BasketWhy You’ll Want to Watch This Stock
Stable cash generation
Merck's established medicines and vaccines often produce predictable revenues and support dividends, though performance can vary with product life cycles and competition.
R&D and pipeline
A deep pipeline, especially in oncology and infectious disease, is a potential long-term growth driver, but clinical and regulatory setbacks remain possible.
Global footprint matters
Broad international presence offers market diversification and scale benefits, while exposure to pricing debates, regulation and litigation can introduce volatility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
